Append Medical

Executive Summary

Append Medical is an early-stage Israeli medical device company developing the Appligator™, a novel transcatheter vacuum system designed to invert and ligate the left atrial appendage (LAA) without leaving a permanent implant. The technology targets stroke prevention in patients with non-valvular atrial fibrillation (NVAF), a condition affecting millions worldwide. Current standard-of-care includes lifelong anticoagulation or implantable LAA occluders, both associated with bleeding risks or long-term device-related complications. Append Medical's implant-free approach aims to eliminate the need for permanent hardware, potentially reducing infection risk, thromboembolism, and follow-up imaging burden. The company's pre-clinical data suggest effective LAA exclusion with a focused, minimally invasive procedure.

Upcoming Catalysts (preview)

• Q4 2026Initiation of first-in-human clinical study60% success
• Q3 2026Presentation of pivotal animal study results at major cardiology conference70% success
• 2027Receipt of FDA Breakthrough Device designation or CE mark timeline clarity50% success